What is Fresenius Med Cr's earnings per share (EPS)?

Fresenius Med Cr (FMCQF) reported diluted earnings per share of $4.06 for fiscal year 2016. This represents a 20.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fresenius Med Cr (FMCQF) Financials

FMCQF

FY2016 annual

Revenue $17.9B +7.0% YoY

Net Income $1.2B +20.8% YoY

EPS (Diluted) $4.06 +20.1% YoY

Free Cash Flow $1.1B +10.2% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2016, ended Dec 31, 2016 Reported Feb 22, 2017 Currency USD FYE December

Newest figures come from the 10-K for FY2016, filed Feb 22, 2017. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FMCQF SEC filings page.

Fresenius Med Cr (FMCQF) reported $17.9B in revenue for fiscal year 2016, up 7.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FMCQF FY2016 2026-08-30

Fresenius Medical Care’s operating leverage combines with heavier reinvestment, while declining leverage offsets tighter short-term liquidity.

FY2016’s operating margin reached 14.7% while FCF margin was only 6.2%, showing that improved operating profitability was partly absorbed by reinvestment rather than passing through to discretionary cash. That gap was little changed from FY2015, when FCF margin was 6.0%, so the margin improvement did not materially alter the cash economics.

The 7.0% sales increase produced 13.4% operating-income growth, consistent with fixed costs being spread across a larger base rather than simple top-line expansion. Operating cash flow of $2.1B versus FCF of $1.1B means capital spending absorbed about half of cash generated from operations, making the profit improvement less visible after reinvestment.

Debt-to-equity fell from 0.8x to 0.7x between FY2015 and FY2016, indicating a less debt-dependent capital structure. The current ratio nevertheless fell to 1.5x as current liabilities rose faster than current assets, separating improved long-term leverage from tighter short-term flexibility.

Financial Health Signals

Financial health score not available

Fresenius Med Cr does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.13

Fresenius Med Cr scores 2.13, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Fresenius Med Cr passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.72x

For every $1 of reported earnings, Fresenius Med Cr generates $1.72 in operating cash flow ($2.1B OCF vs $1.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.83x

Fresenius Med Cr earns $5.83 in operating income for every $1 of interest expense ($2.6B vs $452.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.7B

YoY-43.6%

QoQ+1.9%

Fresenius Med Cr generated $4.7B in revenue in Q4 2016. This represents a decrease of 43.6% from the same quarter a year earlier. Against the prior quarter it is up 1.9%.

EBITDA

$1.4B

YoY+14.4%

QoQ+59.0%

Fresenius Med Cr's EBITDA was $1.4B in Q4 2016, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.4% from the same quarter a year earlier. Against the prior quarter it is up 59.0%.

Net Income

$388.1M

YoY+22.5%

QoQ+16.5%

Fresenius Med Cr reported $388.1M in net income in Q4 2016. This represents an increase of 22.5% from the same quarter a year earlier. Against the prior quarter it is up 16.5%.

EPS (Diluted)

Not reported for Q4 2016.

Cash & Balance Sheet

Free Cash Flow

$561.2M

YoY+131.2%

QoQ+184.4%

5Y CAGR+13.7%

Fresenius Med Cr generated $561.2M in free cash flow in Q4 2016, representing cash available after capex. This represents an increase of 131.2% from the same quarter a year earlier. Against the prior quarter it is up 184.4%.

Cash & Debt

$747.2M

YoY+36.0%

QoQ+18.6%

5Y CAGR+10.3%

Fresenius Med Cr held $747.2M in cash against $7.2B in long-term debt as of Q4 2016.

Shares Outstanding

306M

YoY+0.3%

QoQ+0.2%

5Y CAGR+0.4%

Fresenius Med Cr had 306M shares outstanding in Q4 2016. This represents an increase of 0.3% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q4 2016.

Margins & Returns

Gross Margin

34.0%

YoY-31.4pp

QoQ+2.0pp

Fresenius Med Cr's gross margin was 34.0% in Q4 2016, indicating the percentage of revenue retained after direct costs. This is down 31.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.

Operating Margin

16.8%

YoY+8.8pp

QoQ+2.2pp

Fresenius Med Cr's operating margin was 16.8% in Q4 2016, reflecting core business profitability. This is up 8.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.

Net Margin

8.3%

YoY+4.5pp

QoQ+1.0pp

Fresenius Med Cr's net profit margin was 8.3% in Q4 2016, showing the share of revenue converted to profit. This is up 4.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.

Return on Equity

3.6%

YoY+0.4pp

QoQ+0.4pp

Fresenius Med Cr's ROE was 3.6% in Q4 2016, measuring profit generated per dollar of shareholder equity. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.4 percentage points.

Capital Allocation

R&D Spending

$42.2M

YoY+5.7%

QoQ-3.8%

Fresenius Med Cr invested $42.2M in research and development in Q4 2016. This represents an increase of 5.7% from the same quarter a year earlier. Against the prior quarter it is down 3.8%.

Capital Expenditures

$282.4M

YoY-7.6%

QoQ+16.9%

5Y CAGR+7.0%

Fresenius Med Cr invested $282.4M in capex in Q4 2016, funding long-term assets and infrastructure. This represents a decrease of 7.6% from the same quarter a year earlier. Against the prior quarter it is up 16.9%.

Share Buybacks

Not reported for Q4 2016.

FMCQF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FMCQF quarterly income statement

Metric	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K	FY0810-K	FY0710-K
Revenue	$17.9B+7.0%	$16.7B+217.9%	$5.3B+5.9%	$5.0B-64.0%	$13.8B+9.8%	$12.6B+6.1%	$11.8B+5.3%	$11.2B+6.0%	$10.6B+9.2%	$9.7B
Cost of Revenue	$12.1B+6.4%	$11.4B+5.3%	$10.8B+9.8%	$9.9B+7.3%	$9.2B+9.3%	$8.4B+5.1%	$8.0B+8.0%	$7.4B+6.2%	$7.0B+9.7%	$6.4B
Gross Profit	$5.8B+8.4%	$5.3B+195.7%	-$5.6B-13.7%	-$4.9B-206.5%	$4.6B+10.8%	$4.2B+8.3%	$3.8B+0.1%	$3.8B+5.6%	$3.6B+8.1%	$3.4B
R&D Expenses	$162.4M+15.7%	$140.3M+14.9%	$122.1M-2.9%	$125.8M+12.7%	$111.6M+0.7%	$110.8M+14.8%	$96.5M+2.9%	$93.8M+16.9%	$80.2M+20.6%	$66.5M
SG&A Expenses	$3.0B+5.1%	$2.9B+9.5%	$2.6B+11.0%	$2.4B+7.1%	$2.2B+11.1%	$2.0B+9.8%	$1.8B-8.2%	$2.0B+5.9%	$1.9B+9.8%	$1.7B
Operating Income	$2.6B+13.4%	$2.3B+3.2%	$2.3B-0.1%	$2.3B+1.7%	$2.2B+6.9%	$2.1B+7.9%	$1.9B+9.6%	$1.8B+5.0%	$1.7B+5.8%	$1.6B
EBITDA	$3.4B+12.1%	$3.0B+3.1%	$3.0B+1.7%	$2.9B+2.9%	$2.8B+7.2%	$2.6B+8.5%	$2.4B+9.7%	$2.2B+6.0%	$2.1B+7.4%	$1.9B
Interest Expense	$452.2M-11.0%	$508.0M+2.6%	$495.4M+10.7%	$447.5M-4.9%	$470.5M+32.0%	$356.4M+16.7%	$305.5M-4.9%	$321.4M-11.1%	$361.6M-9.5%	$399.6M
Income Tax	$683.1M+9.8%	$622.1M+6.6%	$583.6M-1.4%	$592.0M-2.2%	$605.1M+0.7%	$601.1M+3.9%	$578.3M+17.9%	$490.4M+3.1%	$475.7M+4.8%	$453.8M
Net Income	$1.2B+20.8%	$1.0B-1.5%	$1.0B-5.8%	$1.1B-6.5%	$1.2B+10.8%	$1.1B+9.5%	$978.5M+9.8%	$891.1M+9.0%	$817.6M+14.0%	$717.1M
EPS (Basic)	$4.07+20.4%	$3.38-2.3%	$3.46-5.2%	$3.65-6.2%	$3.89+9.9%	$3.54+8.9%	$3.25+8.7%	$2.99+8.7%	$2.75+13.2%	$2.43
EPS (Diluted)	$4.06+20.1%	$3.38-2.0%	$3.45-5.5%	$3.65-5.7%	$3.87+10.3%	$3.51+8.3%	$3.24+8.4%	$2.99+9.1%	$2.74+13.2%	$2.42
Diluted Shares (Avg)	306M+0.4%	305M+0.7%	303M+0.1%	303M-0.1%	303M+0.7%	301M+0.9%	298M+1.3%	294M+0.1%	294M	N/A

Metric	Q4'1610-K	Q3'1610-Q	Q2'1610-Q	Q1'1610-Q	Q4'1510-K	Q3'1510-Q	Q2'1510-Q	Q1'1510-Q
Revenue	$4.7B-43.6%	$4.6B+8.7%	$4.4B+5.3%	$4.2B+10.8%	$8.3B	$4.2B+2.9%	$4.2B+9.5%	$3.8B+6.5%
Cost of Revenue	$3.1B+7.5%	$3.1B+9.7%	$3.0B+4.2%	$2.9B-99.9%	$2.9B	$2.8B+0.9%	$2.9B+10.6%	$2.8T+111764.7%
Gross Profit	$1.6B-70.7%	$1.5B+6.5%	$1.4B+7.8%	$1.3B+100.0%	$5.4B	$1.4B+7.3%	$1.3B+7.1%	-$2.8T-256268.4%
R&D Expenses	$42.2M+5.7%	$43.9M+25.6%	$38.8M+12.4%	$37.5M-99.9%	$39.9M	$34.9M+15.6%	$34.5M+12.3%	$30.9B+102930.5%
SG&A Expenses	$767.2M-1.1%	$786.8M+6.0%	$732.1M+1.3%	$758.5M-99.9%	$775.7M	$742.3M+10.6%	$722.6M+14.6%	$654.9B+105577.5%
Operating Income	$786.2M+18.8%	$669.9M+9.2%	$641.1M+17.2%	$540.3M-99.9%	$661.8M	$613.5M+4.0%	$547.0M-1.7%	$504.4B+113275.1%
EBITDA	$1.4B+14.4%	$866.5M+9.2%	$446.9M+22.1%	$722.1M-99.9%	$1.2B	$793.4M+92.3%	$366.0M-5.5%	$680.3B+111041.4%
Interest Expense	$106.0M-15.1%	$109.9M+3.7%	$119.9M+4.2%	$116.4M-99.9%	$124.9M	$105.9M-4.3%	$115.1M+3.4%	$162.0B+145005.5%
Income Tax	$212.2M+17.6%	$164.2M-2.5%	$168.4M+24.4%	$138.3M-99.9%	$180.5M	$168.4M+4.2%	$135.4M-23.6%	$137.9B+136013.3%
Net Income	$388.1M+22.5%	$333.2M+27.0%	$293.9M+22.1%	$228.0M-99.9%	$316.8M	$262.3M-3.1%	$240.8M+3.0%	$209.5B+101888.7%
EPS (Basic)	N/A	N/A	N/A	$0.75+8.7%	$1.04-6.3%	$0.86-3.4%	$0.79+2.6%	$0.69+1.5%
EPS (Diluted)	N/A	N/A	N/A	$0.75	$1.04-5.5%	$0.86-3.4%	N/A	$0.69
Diluted Shares (Avg)	N/A	307M+0.4%	306M+0.1%	306M	N/A	305M+0.6%	305M+1.0%	305M+1.1%

FMCQF Balance Sheet

FMCQF quarterly balance sheet

Metric	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K	FY0810-K	FY0710-K
Total Assets	$26.9B+6.2%	$25.4B-0.1%	$25.4B+9.8%	$23.1B+3.6%	$22.3B+14.3%	$19.5B+14.3%	$17.1B+8.0%	$15.8B+6.0%	$14.9B	N/A
Current Assets	$7.3B+8.1%	$6.8B+0.7%	$6.7B+6.9%	$6.3B+2.6%	$6.1B+7.6%	$5.7B+10.5%	$5.2B+9.0%	$4.7B+12.2%	$4.2B	N/A
Cash & Equivalents	$747.2M+36.0%	$549.5M-13.3%	$633.9M-7.2%	$682.8M-0.8%	$688.0M+50.5%	$457.3M-12.5%	$522.9M+73.6%	$301.2M+35.9%	$221.6M-9.4%	$244.7M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.4B+5.2%	$1.3B+20.2%	$1.1B+1.7%	$1.1B+5.8%	$1.0B+7.2%	$967.5M+19.6%	$809.1M-1.5%	$821.7M+16.2%	$707.0M	N/A
Accounts Receivable	$3.5B+7.3%	$3.3B+2.5%	$3.2B+5.5%	$3.0B+0.6%	$3.0B+7.9%	$2.8B+8.7%	$2.6B+12.6%	$2.3B+5.0%	$2.2B	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$13.7B+4.9%	$13.0B-0.4%	$13.1B+12.2%	$11.7B+2.1%	$11.4B+24.3%	$9.2B+5643.5%	$159.9M-97.9%	$7.5B+2.8%	$7.3B	N/A
Total Liabilities	$14.2B+2.9%	$13.8B-4.7%	$14.5B+11.9%	$13.0B+3.1%	$12.6B+13.9%	$11.1B+19.1%	$9.3B+5.7%	$8.8B-0.1%	$8.8B	N/A
Current Liabilities	$5.0B+21.4%	$4.1B+19.3%	$3.5B-2.2%	$3.6B+12.1%	$3.2B-25.6%	$4.3B+12.5%	$3.8B+45.2%	$2.6B-17.0%	$3.1B	N/A
Non-Current Liabilities	$9.2B-5.1%	$9.7B-12.3%	$11.1B+17.2%	$9.4B+0.1%	$9.4B+38.6%	$6.8B+23.6%	$5.5B-11.0%	$6.2B+9.4%	$5.7B	N/A
Long-Term Debt	$7.2B-8.3%	$7.9B-12.9%	$9.0B+16.4%	$7.7B-0.5%	$7.8B+41.7%	$5.5B+27.5%	$4.3B-2.7%	$4.4B+11.9%	$4.0B	N/A
Total Equity	$10.8B+9.3%	$9.9B+4.7%	$9.4B+2.3%	$9.2B+3.3%	$8.9B+13.2%	$7.9B+7.1%	$7.4B+10.5%	$6.7B+12.0%	$6.0B+7.1%	$5.6B
Retained Earnings	$8.8B+12.3%	$7.9B+10.8%	$7.1B+11.4%	$6.4B+14.6%	$5.6B+19.7%	$4.6B+20.5%	$3.9B+24.0%	$3.1B+26.9%	$2.5B	N/A

Metric	Q4'1610-K	Q3'1610-Q	Q2'1610-Q	Q1'1610-Q	Q4'1510-K	Q3'1510-Q	Q2'1510-Q	Q1'1510-Q
Total Assets	$26.9B+6.2%	$26.7B+4.9%	$26.6B+4.5%	$26.1B-99.9%	$25.4B-0.1%	$25.4B+4.8%	$25.4B+5.2%	$25.1T+107089.9%
Current Assets	$7.3B+8.1%	$7.2B+6.8%	$7.3B+8.6%	$7.1B-99.9%	$6.8B+0.7%	$6.8B+4.7%	$6.7B-1.5%	$6.6T+101479.2%
Cash & Equivalents	$747.2M+36.0%	$629.8M+1.4%	$722.7M+24.1%	$517.8M-99.9%	$549.5M-13.3%	$621.4M+5.8%	$582.2M-9.7%	$622.9B+108399.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.4B+5.2%	$1.4B+6.5%	$1.4B+14.6%	$1.4B-99.9%	$1.3B+20.2%	$1.3B+11.4%	$1.2B-5.6%	$1.2T+95983.3%
Accounts Receivable	$3.5B+7.3%	$3.6B+10.0%	$3.5B+6.2%	$3.6B-99.9%	$3.3B+2.5%	$3.3B+4.3%	$3.3B+2.8%	$3.2T+102817.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$13.7B+4.9%	$13.5B+3.5%	$13.4B+2.7%	$13.2B-99.9%	$13.0B-0.4%	$13.0B+5.5%	$13.1B+10.1%	$13.0T+111691.0%
Total Liabilities	$14.2B+2.9%	$14.2B-0.1%	$14.5B+0.9%	$14.2B-99.9%	$13.8B-4.7%	$14.2B+3.5%	$14.4B+3.9%	$14.1T+107760.0%
Current Liabilities	$5.0B+21.4%	$5.3B+33.5%	$4.9B+36.1%	$4.4B-99.9%	$4.1B+19.3%	$3.9B-8.4%	$3.6B-1.9%	$3.5T+102762.9%
Non-Current Liabilities	$9.2B-5.1%	$8.9B-13.0%	$9.6B-10.9%	$9.7B-8.2%	$9.7B-12.3%	$10.3B+9.0%	$10.8B+6.1%	$10.6B+9.6%
Long-Term Debt	$7.2B-8.3%	$7.2B-14.1%	$7.7B-12.4%	$7.8B-99.9%	$7.9B-12.9%	$8.4B+8.3%	$8.8B+4.2%	$8.6T+107204.0%
Total Equity	$10.8B+9.3%	$10.6B+10.0%	$10.2B+6.3%	$10.2B-99.9%	$9.9B+4.7%	$9.6B+1.5%	$9.6B+2.0%	$9.6T+101243.3%
Retained Earnings	$8.8B+12.3%	$8.4B+11.8%	$8.1B+11.3%	$8.1B-99.9%	$7.9B+10.8%	$7.6B+11.6%	$7.3B+12.2%	$7.3T+111011.4%

FMCQF Cash Flow Statement

FMCQF quarterly cash flow statement

Metric	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K	FY0810-K	FY0710-K
Operating Cash Flow	$2.1B+9.2%	$2.0B+5.3%	$1.9B-8.5%	$2.0B-0.2%	$2.0B+41.0%	$1.4B+5.7%	$1.4B+2.2%	$1.3B+31.7%	$1.0B-15.3%	$1.2B
Depreciation & Amortization	$775.9M+8.2%	$717.3M+2.6%	$699.3M+7.9%	$648.2M+7.5%	$602.9M+8.2%	$557.3M+10.7%	$503.2M+10.1%	$457.1M+10.0%	$415.7M+14.4%	$363.3M
Stock-Based Compensation	$25.7M+290.3%	$6.6M+4.4%	$6.3M-53.6%	$13.6M+489.5%	$2.3M-11.4%	$2.6M0.0%	$2.6M+69.4%	$1.5M-29.8%	$2.2M	N/A
Capital Expenditures	$1.0B+8.1%	$952.9M+2.3%	$931.6M+24.6%	$747.9M+10.8%	$675.3M+13.0%	$597.9M+14.2%	$523.6M-8.7%	$573.6M-16.5%	$687.4M+20.0%	$572.7M
Free Cash Flow	$1.1B+10.2%	$1.0B+8.3%	$929.8M-27.7%	$1.3B-5.6%	$1.4B+60.7%	$848.6M+0.5%	$844.5M+10.4%	$765.0M+132.5%	$329.0M-47.5%	$626.9M
Investing Cash Flow	-$1.4B-37.8%	-$1.0B+62.8%	-$2.7B-123.2%	-$1.2B+47.2%	-$2.3B+2.8%	-$2.3B-108.5%	-$1.1B-61.2%	-$698.0M+21.7%	-$891.4M-14.7%	-$777.0M
Financing Cash Flow	-$584.8M+42.0%	-$1.0B-225.2%	$805.0M+199.6%	-$808.0M-272.5%	$468.3M-41.0%	$793.2M+5489.4%	-$14.7M+97.4%	-$558.1M-257.6%	-$156.1M+54.2%	-$340.7M
Dividends Paid	-$277.2M-5.3%	-$263.2M+17.2%	-$317.9M-7.4%	-$296.1M-209.0%	$271.7M-3.2%	$280.6M+21.0%	$232.0M0.0%	$231.9M-8.1%	$252.4M+34.0%	$188.4M

Metric	Q4'1610-K	Q3'1610-Q	Q2'1610-Q	Q1'1610-Q	Q4'1510-K	Q3'1510-Q	Q2'1510-Q	Q1'1510-Q
Operating Cash Flow	$843.6M+53.8%	$438.9M-24.2%	$677.6M	$179.8M-100.0%	$548.3M-6.7%	$579.3M-18.7%	$0-100.0%	$832.5B+741213.0%
Depreciation & Amortization	$203.4M+12.6%	$196.6M+9.3%	-$194.2M-7.3%	$181.8M-99.9%	$180.7M-2.8%	$179.8M+201.4%	-$181.0M-7.1%	$175.9B+105096.6%
Capital Expenditures	$282.4M-7.6%	$241.5M+5.2%	$756.3M-9.5%	-$250.2M-99.9%	$305.6M-80.6%	$229.6M-78.5%	$835.5M+280.4%	-$417.8B+209161.6%
Free Cash Flow	$561.2M+131.2%	$197.3M-43.6%	-$78.6M+90.6%	-$70.4M-100.0%	$242.7M+124.5%	$349.7M+198.9%	-$835.5M-463.8%	$414.7B+474926.2%
Investing Cash Flow	-$451.4M-87.1%	-$272.6M+3.3%	-$318.2M	-$337.1M+99.9%	-$241.3M+76.0%	-$281.8M+66.4%	$0+100.0%	-$477.6B-143785.9%
Financing Cash Flow	-$266.9M+28.5%	-$266.5M-10.8%	-$166.3M	$114.9M+100.0%	-$373.3M-175.1%	-$240.5M-496.6%	$0-100.0%	-$393.8B-338945.7%
Dividends Paid	-$554.4M-5.3%	$554.4M+5.3%	-$277.2M-205.3%	$0+100.0%	-$526.5M	$526.5M+65.6%	$263.2M-17.2%	-$263.2B

Not reported in any period shown, so not listed: Stock-Based Compensation, Share Buybacks.

FMCQF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FMCQF quarterly financial ratios

Metric	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K	FY0910-K	FY0810-K	FY0710-K
Gross Margin	32.3%+0.4pp	31.9%	-105.8%	-98.6%-131.9pp	33.3%+0.3pp	33.0%+0.7pp	32.4%-1.7pp	34.1%-0.1pp	34.2%-0.3pp	34.5%
Operating Margin	14.7%+0.8pp	13.9%-28.9pp	42.8%-2.6pp	45.4%+29.3pp	16.1%-0.4pp	16.5%+0.3pp	16.2%+0.6pp	15.6%-0.2pp	15.8%-0.5pp	16.3%
Net Margin	6.9%+0.8pp	6.2%-13.7pp	19.9%-2.5pp	22.3%+13.7pp	8.6%+0.1pp	8.5%+0.3pp	8.3%+0.3pp	7.9%+0.2pp	7.7%+0.3pp	7.4%
Return on Equity	11.5%+1.1pp	10.4%-0.7pp	11.1%-0.9pp	12.0%-1.3pp	13.3%-0.3pp	13.6%+0.3pp	13.3%-0.1pp	13.4%-0.4pp	13.7%+0.8pp	12.9%
Return on Assets	4.6%+0.6pp	4.1%-0.1pp	4.1%-0.7pp	4.8%-0.5pp	5.3%-0.2pp	5.5%-0.2pp	5.7%+0.1pp	5.6%+0.2pp	5.5%	N/A
Current Ratio	1.45-0.2x	1.63-0.3x	1.93+0.2x	1.77-0.2x	1.93+0.6x	1.340.0x	1.36-0.5x	1.81+0.5x	1.34	N/A
Debt-to-Equity	0.67-0.1x	0.79-0.2x	0.95+0.1x	0.840.0x	0.87+0.2x	0.70+0.1x	0.58-0.1x	0.660.0x	0.66	N/A
Asset Turnover	0.670.0x	0.66+0.5x	0.210.0x	0.21-0.4x	0.620.0x	0.640.0x	0.690.0x	0.710.0x	0.71	N/A
FCF Margin	6.2%+0.2pp	6.0%-11.6pp	17.7%-8.2pp	25.9%+16.0pp	9.9%+3.1pp	6.8%-0.4pp	7.1%+0.3pp	6.8%+3.7pp	3.1%-3.4pp	6.5%

Metric	Q4'1610-K	Q3'1610-Q	Q2'1610-Q	Q1'1610-Q	Q4'1510-K	Q3'1510-Q	Q2'1510-Q	Q1'1510-Q
Gross Margin	34.0%-31.4pp	32.0%-0.7pp	31.6%+0.7pp	31.3%	65.3%	32.7%+1.3pp	30.9%-0.7pp	-73007.1%
Operating Margin	16.8%+8.8pp	14.6%+0.1pp	14.5%+1.5pp	12.8%	8.0%	14.5%+0.2pp	13.0%-1.5pp	13284.2%
Net Margin	8.3%+4.5pp	7.2%+1.0pp	6.7%+0.9pp	5.4%	3.8%	6.2%-0.4pp	5.7%-0.4pp	5518.8%
Return on Equity	3.6%+0.4pp	3.1%+0.4pp	2.9%+0.4pp	2.2%0.0pp	3.2%	2.7%-0.1pp	2.5%0.0pp	2.2%0.0pp
Return on Assets	1.4%+0.2pp	1.3%+0.2pp	1.1%+0.2pp	0.9%0.0pp	1.3%	1.0%-0.1pp	0.9%0.0pp	0.8%0.0pp
Current Ratio	1.45-0.2x	1.37-0.3x	1.48-0.4x	1.61-0.3x	1.63-0.3x	1.72+0.2x	1.850.0x	1.860.0x
Debt-to-Equity	0.67-0.1x	0.68-0.2x	0.76-0.2x	0.77-0.1x	0.79-0.2x	0.87+0.1x	0.920.0x	0.900.0x
Asset Turnover	0.17-0.2x	0.170.0x	0.170.0x	0.16+0.2x	0.33	0.170.0x	0.170.0x	0.00-0.2x
FCF Margin	12.0%+9.0pp	4.3%-4.0pp	-1.8%+18.1pp	-1.7%	2.9%	8.3%+16.9pp	-19.9%-25.9pp	10921.8%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Where Fresenius Med Cr Ranks

Frequently Asked Questions

What is Fresenius Med Cr's annual revenue?

Fresenius Med Cr (FMCQF) reported $17.9B in total revenue for fiscal year 2016. This represents a 7.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fresenius Med Cr's revenue growing?

Fresenius Med Cr (FMCQF) revenue grew by 7.0% year-over-year, from $16.7B to $17.9B in fiscal year 2016.

Is Fresenius Med Cr profitable?

Yes, Fresenius Med Cr (FMCQF) reported a net income of $1.2B in fiscal year 2016, with a net profit margin of 6.9%.

What is Fresenius Med Cr's EBITDA?

Fresenius Med Cr (FMCQF) had EBITDA of $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Fresenius Med Cr have?

As of fiscal year 2016, Fresenius Med Cr (FMCQF) had $747.2M in cash and equivalents against $7.2B in long-term debt.

What is Fresenius Med Cr's gross margin?

Fresenius Med Cr (FMCQF) had a gross margin of 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fresenius Med Cr's operating margin?

Fresenius Med Cr (FMCQF) had an operating margin of 14.7% in fiscal year 2016, reflecting the profitability of core business operations before interest and taxes.

What is Fresenius Med Cr's net profit margin?

Fresenius Med Cr (FMCQF) had a net profit margin of 6.9% in fiscal year 2016, representing the share of revenue converted into profit after all expenses.

Does Fresenius Med Cr pay dividends?

Yes, Fresenius Med Cr (FMCQF) paid $0.80 per share in dividends during fiscal year 2016.

What is Fresenius Med Cr's return on equity (ROE)?

Fresenius Med Cr (FMCQF) has a return on equity of 11.5% for fiscal year 2016, measuring how efficiently the company generates profit from shareholder equity.

What is Fresenius Med Cr's free cash flow?

Fresenius Med Cr (FMCQF) generated $1.1B in free cash flow during fiscal year 2016. This represents a 10.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Fresenius Med Cr's operating cash flow?

Fresenius Med Cr (FMCQF) generated $2.1B in operating cash flow during fiscal year 2016, representing cash generated from core business activities.

What are Fresenius Med Cr's total assets?

Fresenius Med Cr (FMCQF) had $26.9B in total assets as of fiscal year 2016, including both current and long-term assets.

What are Fresenius Med Cr's capital expenditures?

Fresenius Med Cr (FMCQF) invested $1.0B in capital expenditures during fiscal year 2016, funding long-term assets and infrastructure.

How much does Fresenius Med Cr spend on research and development?

Fresenius Med Cr (FMCQF) invested $162.4M in research and development during fiscal year 2016.

How many shares does Fresenius Med Cr have outstanding?

Fresenius Med Cr (FMCQF) had 306M shares outstanding as of fiscal year 2016.

What is Fresenius Med Cr's current ratio?

Fresenius Med Cr (FMCQF) had a current ratio of 1.45 as of fiscal year 2016, which is considered adequate.

What is Fresenius Med Cr's debt-to-equity ratio?

Fresenius Med Cr (FMCQF) had a debt-to-equity ratio of 0.67 as of fiscal year 2016, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fresenius Med Cr's return on assets (ROA)?

Fresenius Med Cr (FMCQF) had a return on assets of 4.6% for fiscal year 2016, measuring how efficiently the company uses its assets to generate profit.

What is Fresenius Med Cr's Altman Z-Score?

Fresenius Med Cr (FMCQF) has an Altman Z-Score of 2.13, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Fresenius Med Cr's Piotroski F-Score?

Fresenius Med Cr (FMCQF) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fresenius Med Cr's earnings high quality?

Fresenius Med Cr (FMCQF) has an earnings quality ratio of 1.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fresenius Med Cr cover its interest payments?

Fresenius Med Cr (FMCQF) has an interest coverage ratio of 5.83x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.